Compare Quest Diagnostics Inc (DGX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs UiPath Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.95B), while UiPath Inc trades at $11.98 (market cap $6.14B). The key difference: Quest Diagnostics Inc is far larger — about 3.7× UiPath Inc's market cap, and Quest Diagnostics Inc pays a 1.66% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| DGX | PATH | |
|---|---|---|
Market Cap | $22.95B | $6.14B |
Sector | Health | Technology |
52-Week High | $216.02 | $19.29 |
52-Week Low | $166.42 | $9.38 |
Enterprise Value | $28.97B | $4.92B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UiPath (PATH) trades at $11.85, up 1.46% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent earnings show mixed results with Q1 2026 missing expectations but strong gross margins of 83.01% highlight operational efficiency. Analyst consensus price target sits at $13.33 with 25% buy ratings.
PATH presents a compelling turnaround story with accelerating revenue growth and path to profitability. Key opportunities include agentic AI adoption through Maestro platform and expanding enterprise automation. Risks include execution challenges in AI monetization, competitive pressures, and the stock's premium valuation multiples requiring sustained growth delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
